Eric Marandett and Mark Edgarton on The Preserve Access to Affordable Generics Act

IP Law360

 | April 9, 2009

 | Eric Marandett and Mark Edgarton

View "Consequences of Banning Reverse Payments"


Eric Marandett, chair of intellectual property litigation, and Mark Edgarton, partner in intellectual property litigation, co-wrote “Consequences of Banning Reverse Payments,” published in the IP, Competition and Health sections of Law360

In the guest column, Mr. Marandett and Mr. Edgarton analyze various potential effects of The Preserve Access to Affordable Generics Act currently being debated in the Senate.  The column also summarizes relevant legislation and decisions, and it examines reasons for the longstanding disagreement between the DOJ and FTC on the propriety of reverse-payment settlements of Hatch-Waxman litigation. 




Thank you for reaching out to contact Choate. Before you send your message, we wanted to make sure you are aware of the following. Please do not send any confidential information in response to this link. Sending an e-mail to Choate does not give rise to an attorney-client relationship, and will not be deemed to disqualify Choate from undertaking any engagement for a current or future client.  Before any attorney-client engagement may be formed, Choate will need to check for possible conflicts of interest, you will need to consider whether you wish to retain Choate as counsel, and we will need to consider whether we wish to accept the potential engagement. In the meantime, Choate reserves the right to represent parties with interests adverse to you.